Drug Interactions between Cycrin and neratinib
This report displays the potential drug interactions for the following 2 drugs:
- Cycrin (medroxyprogesterone)
Interactions between your drugs
Applies to: Cycrin (medroxyprogesterone) and neratinib
Neratinib may reduce the blood levels and effectiveness of medroxyPROGESTERone, which may make it less reliable as a form of birth control. Alternative or additional methods of birth control such as condoms should be used during treatment with neratinib and for up to 1 month after stopping treatment to avoid unintended pregnancy. Talk to your gynecologist or other healthcare professional for help in selecting an effective method of birth control that is best for you. If you take hormone replacement for menopause, you should contact your doctor if you experience increased frequency or worsening of your symptoms such as hot flashes, vaginal dryness, or abnormal bleeding. Men receiving neratinib should also use a condom during the treatment period and for 3 months after stopping treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
Applies to: neratinib
Grapefruit juice can increase the blood levels of neratinib. This may increase the risk and/or severity of side effects such as diarrhea, nausea, vomiting, abdominal pain, mouth sores, loss of appetite, and liver problems. You should avoid the consumption of grapefruit and grapefruit juice during treatment with neratinib. Be sure to take the medication with food at the same time everyday to maintain consistent blood levels and effects. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.